ArticlePaediatric drugs2009
The National Institutes of Health and the Best Pharmaceuticals for Children Act.
Article in Paediatric drugs, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 26 citations in OpenAlex.
- Opportunities in the translational pipeline for pediatric brain cancer therapies.Pediatric research · 2025Review
- Article
- How to Conduct Clinical Trials in Children: A Tutorial.Clinical and translational science · 2019Article
- Pediatric Biopharmaceutical Classification System: Using Age-Appropriate Initial Gastric Volume.The AAPS journal · 2016Article
- Academic pediatric clinical research: factors associated with study implementation duration.BMC medical research methodology · 2016Article
- Dosing in neonates: special considerations in physiology and trial design.Pediatric research · 2015Review
- LC-UV/MS quality analytics of paediatric artemether formulations.Journal of pharmaceutical analysis · 2014Article
- Article
- Summary of the National Institute of Child Health and Human Development-best pharmaceuticals for Children Act Pediatric Formulation Initiatives Workshop-Pediatric Biopharmaceutics Classification System Working Group.Clinical therapeutics · 2012Review
- Clinical research careers: reports from a NHLBI pediatric heart network clinical research skills development conference.American heart journal · 2011Review
- Challenges in conducting clinical trials in children: approaches for improving performance.Expert review of clinical pharmacology · 2009Article
- Patterns of Off-Label Prescribing in the Pediatric Intensive Care Unit and Prioritizing Future Research.The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAGArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The majority of drugs used to treat children are not labeled for use in children. The Best Pharmaceuticals for Children Act of 2002, re-authorized as the US FDA Amendments Act of 2007, directs the National Institutes of Health (NIH) to sponsor pediatric clinical trials of drugs lacking patent protection, if the FDA request for studies has been declined. The NIH is currently sponsoring 17 clinical studies. Challenges encountered include a paucity of investigators who are trained in pediatric clinical pharmacology; inadequate knowledge of the mechanisms of drug action in a growing child; and lack of pediatric formulations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.